CME Travel Academy

GINA 2026 Asthma Update featured image with key stats: ICS-formoterol AIR, four new primary-care exacerbation flowcharts, depemokimab Q26-week dosing.

GINA 2026: What’s New in Asthma Management for Primary Care

The Global Initiative for Asthma (GINA) released its 2026 Strategy Report on May 5, 2026, and primary care is squarely in its crosshairs. Asthma affects roughly 25 million Americans, and the majority of routine management still happens in family medicine, internal medicine, and advanced-practice offices rather than in pulmonology subspecialty suites. The 2026 update reflects […]

GINA 2026: What’s New in Asthma Management for Primary Care Read More »

GLP-1 Receptor Agonists in Obese HFpEF: What the STEP-HFpEF and SUMMIT Trials Mean for Your Practice

Heart failure with preserved ejection fraction (HFpEF) now accounts for more than half of all heart failure diagnoses in the United States, and the proportion continues to rise alongside the obesity epidemic. For decades, clinicians managing this phenotype had few effective pharmacologic tools — spironolactone and SGLT-2 inhibitors offered modest benefit in selected patients, but

GLP-1 Receptor Agonists in Obese HFpEF: What the STEP-HFpEF and SUMMIT Trials Mean for Your Practice Read More »